

ASX:NRT

NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:
186 M

Board of Directors

Dr Graham Kelly
Chairman &
Executive Director

Steve Coffey
Non-Executive Director

John O'Connor
Non-Executive Director

Prof Peter Gunning
Non-Executive Director

ASX RELEASE

4 December 2014

Novogen Receives \$1.54M R&D Tax Incentive

4 December 2014, Sydney, Australia: Novogen Limited (ASX:NRT; NASDAQ:NVGN) has received \$1.54M from the Australian Taxation Office under the Research and Development Tax Incentive Program relating to the financial year ending 30 June 2014.

The funds will be applied to working capital and towards the costs of bringing lead candidate product, Cantrixil, into its first-in-man study in late-stage ovarian cancer.

Dr Graham Kelly, Novogen Group CEO, said, "This money, combined with the \$1.9M raised recently on top of our existing cash reserves, will underpin the Company's transition into a clinical stage company. It also is providing the Company with time to evaluate a wide range of funding options currently on the table, with the intention to fund the Company's operations well into 2016 and expand its clinical program to include the treatment of brain cancer, melanoma, and prostate cancer."

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly
Executive Chairman & CEO Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys
Operations Manager Novogen Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472 4111